ache.

ACHE Inhibitor 12 inhibited acetylcholinesterase with an IC50 value of 0.38 µM.

ACHE-IN-38 is a potent Acetylcholinesterase inhibitor that can be used for the synthesis of compounds with anti-inflammatory, anti-tumor, and antibacterial activities.

AChE-IN-23 (compound 3h) is an acetylcholinesterase (AChE) inhibitor with an IC50 value of 48.3 μM [1].

AChE-IN-3 had inhibitory effect on AChE and stronger inhibitory effect on NO, with EC50 of 0.57 μM.

AChE BChE MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE, and MAO-B that crosses the blood-brain barrier, exhibiting inhibitory effects on hAChE, hBChE, and hMAO-B with IC50s of 7.31, 0.56, and 26.1 μM, respectively. [AChE BChE MAO-B-IN-1] had a neuroprotective effect and was not significantly cytotoxic.

AChE BuChE-IN-4 is a multi-target AChE BuChE inhibitor with oral activity and blood-brain barrier permeability, with IC50 values of 2.08 and 7.41 μM for AChE and BuChE, respectively.

AChE-IN-27 is a small molecule used for high-throughput assays.

AChE BChE-IN-21 is an antagonist of the histamine H3 receptor, a calcium channel blocker, and an acetylcholinesterase inhibitor. It exhibits neuroprotective activities against H2O2 and Aβ1-40, and can restore cognitive functions in AD mice.

AChE-IN-73 (compound 6), an insecticide, exhibits potent mosquito inhibitory capabilities, particularly against C. pipiens with an LC 50 of 78.0 mg L. It demonstrates high affinity for acetylcholinesterase (AChE) and nicotinic acetylcholine receptors (nAChR), with respective binding energies of -8.11 kcal mol and -6.27 kcal mol.

AChE-IN-75 (N-(2'-methyl)allylnorgalanthamine) is an AChE inhibitor utilized in Alzheimer's disease research.

AChE-IN-77 (5d) serves as an effective inhibitor of both AChE and BACE1, exhibiting IC50 values of 29.46 µM and 2.85 µM, respectively. It also demonstrates metal chelating ability towards Fe3+ in vitro.

AChE-IN-76 (compound 6) is an acetylcholinesterase inhibitor with an IC50 of 7.6 nM.

AChE BChE-IN-22 (compound 7) exhibits competitive inhibition against both AChE and BChE enzymes, with inhibition constants of 28.18 μM and 41.74 μM respectively.

AChE-IN-79 (compound 3i) is an acetylcholinesterase inhibitor with an IC50 of 2.7 µM, suitable for studies related to Alzheimer's disease.

AChE CA I-IN-1 (Compound 2g) acts as an inhibitor for both AChE and hCA I, with Ki values of 1.85 µM and 0.53 µM, respectively. It has shown potential applications in the research of Alzheimer's disease, glaucoma, and epilepsy.

AChE BChE-IN-23 (Compound 6e) is a dual inhibitor of acetylcholinesterase and butyrylcholinesterase, exhibiting IC50 values of 0.91 μM for AChE, 1.19 μM for eqBChE, and 1.01 μM for hBChE. This compound also demonstrates antioxidant properties and inhibits the aggregation of Aβ1-42 and Tau proteins. Moreover, AChE BChE-IN-23 prevents the activation of microglial cells by inhibiting the release of reactive oxygen species and mitochondrial damage. Additionally, it reduces the levels of the NLRP3 inflammasome in human microglial cells and reverses memory impairment in mice induced by scopolamine.

AChE BChE-IN-24 (compound 5k) functions as a neuroprotective agent by inhibiting acetylcholinesterase. It targets both AChE and BChE, demonstrating IC50 values of 16.38 μM and 10.44 μM, respectively.

AChE BChE-IN-25 (Compound 6e) is an orally active inhibitor of hAChE and eqBChE, with IC50 values of 7.9 nM and 0.79 nM, respectively. This compound exhibits antioxidant activity, effective in scavenging free radicals with an IC50 of 22.91 μM. AChE BChE-IN-25 demonstrates neuroprotective effects by reducing mitochondrial and cellular oxidative stress in a Drosophila Alzheimer's model and improves spatial and cognitive memory impairments induced by Scopolamine in mouse models.

AChE BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and BuChE, with IC50 values of 1.24 and 1.85 μg mL, respectively. It exhibits strong DPPH radical scavenging activity (IC50 = 3.15 μg mL). In vivo toxicity studies demonstrate that AChE BuChE-IN-6 is safe, showing no significant differences in blood and biochemical parameters compared to controls, and no abnormalities in liver and kidney tissues. This compound shows potential for Alzheimer's disease research.

AChE hCA I-IN-1 (Compound L3) is an inhibitor of acetylcholinesterase (AChE) and carbonic anhydrase (CA), effectively inhibiting AChE, hCA I, and hCA II with IC50 values of 302 nM, 265 nM, and 283 nM, respectively.

AChE-IN-80 (Compound 1) is an inhibitor of acetylcholinesterase (AChE). It suppresses inflammation and reactive oxygen species (ROS) production in cultured neurons and microglia, induces autophagy, and prevents the spread of beta-amyloid (Aβ) fibrils. AChE-IN-80 exhibits antioxidant activity and neuroprotective effects, making it valuable for Alzheimer's disease research.

AChE MAO-B-IN-7 (VAV-8) is a compound that acts as a dual inhibitor of acetylcholinesterase (AChE) and MAO-B, with the ability to cross the blood-brain barrier. It also inhibits the aggregation of Aβ42, making it a valuable compound for Alzheimer's disease (AD) research.

AChE-IN-81 (compound 22) is a reversible, selective inhibitor of AChE with an 80.0% inhibition rate and an IC50 of 3.7 μM. It binds to AChE with an affinity (Kd) of 5.37 μM. AChE-IN-81 effectively reduces apoptosis in zebrafish brain cells and shows potential neuroprotective activity in an H2O2-induced SH-SY5Y cell damage model.

AChE-IN-84 (compound 21) is an inhibitor of AChE.